Not Yet RecruitingNot Applicable

Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints

60 participantsStarted 2026-04

Plain-language summary

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence. It causes irreversible central vision loss and significant difficulties in daily activities, impairing patients' quality of life and independence. Conventional clinical assessments, which focus on visual acuity and retinal imaging, do not fully reflect the functional impact of the disease. Virtual reality (VR) makes it possible to create immersive, controlled environments to accurately measure functional vision and simulate real-life situations. The study proposes to develop a standardized and reproducible functional test in virtual reality that can complement conventional examinations and support clinical and industrial research.

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 50 years * Sufficient knowledge of the French language * Ability to give personal, express, free, and informed consent * Ability to comply with the requirements of the protocol * Person covered by Social Security * Clarity of the ocular environment, adequate pupil dilation to allow the collection of good quality images, as determined by the investigator Additional inclusion criteria for group 1, healthy subjects: * No detectable visual pathologies * Best monocular visual acuity ≥ 8/10 Additional inclusion criteria for group 2, subjects with LMA, early AMD, or intermediate AMD without atrophy: * Diagnosis of AMD, early AMD, or intermediate AMD * Absence of geographic atrophy * Presence of drusen (diameter \> 63 µm) with or without pigmentary changes Additional inclusion criteria for group 3, subjects with dry AMD with perifoveal atrophy: * Diagnosis of atrophic AMD * Presence of drusen (diameter \> 125 µm) * Location of geographic atrophy as determined by the investigator: extrafoveal, juxtafoveal * Preservation of central vision confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations. Additional inclusion criteria for group 4, Subject with dry AMD with foveal atrophy: * Diagnosis of atrophic AMD * Presence of drusen (diameter \> 125 µm) * Investigator's localization of geographic atrophy: retrofoveal * Central vision impairment confirme…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of Net selection assessed by the SPOT test

Timeframe: Baseline

Number of Net selection assessed by the SPOT test

Timeframe: Hour 1

Number of target selection assessed by the SPOT test

Timeframe: Baseline

Number of target selection assessed by the SPOT test

Timeframe: Hour 1

Trial details

NCT IDNCT07433088

SponsorStreetlab

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-04

View on ClinicalTrials.gov More Dry AMD trials